RedHill Biopharma Ltd.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M | $6.5M | $61.8M | $85.8M | $64.4M | $6.3M | $8.4M | $4.0M |
| Cost of Revenue | $3.2M | $3.5M | $33.3M | $49.4M | $36.9M | $2.3M | $2.8M | $2.1M |
| Gross Profit | $4.9M | $3.1M | $28.5M | $36.4M | $27.5M | $4.0M | $5.5M | $1.9M |
| Gross Margin | 60.3% | 47.0% | 46.1% | 42.4% | 42.7% | 64.1% | 66.1% | 46.9% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-14.6M | $12.6M | $-42.8M | $-81.1M | $-63.7M | $-43.2M | $-39.3M | $-52.0M |
| Operating Margin | -181.7% | 193.4% | -69.3% | -94.6% | -99.0% | -686.7% | -470.5% | -1,297.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-8.3M | $23.9M | $-71.7M | $-97.7M | $-76.2M | $-42.3M | $-38.8M | $-45.5M |
| Net Margin | -102.8% | 366.2% | -116.0% | -114.0% | -118.4% | -672.5% | -464.4% | -1,136.6% |
| EPS (Basic) | $0.00 | $0.01 | $-0.12 | $-0.21 | $-0.21 | $-0.14 | $-0.17 | $-0.26 |
| EPS (Diluted) | $0.00 | $0.01 | $-0.12 | $-0.21 | $-0.21 | $-0.14 | $-0.17 | $-0.26 |
| Shares Outstanding (Basic) | 12.90B | 12.75B | 1.18B | 526.8M | 384.0M | 352.7M | 283.7M | 212.7M |
| Shares Outstanding (Diluted) | 12.90B | 12.75B | 1.18B | 526.8M | 384.0M | 352.7M | 283.7M | 212.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |